Actelion Reports Further Progress to Additional Markets for Tracleer in Pulmonary Arterial Hypertension
December 15, 2003 01:14 ET
|
Actelion Ltd.
ALLSCHWIL and BASEL, Switzerland, Dec. 15, 2003 (PRIMEZONE) -- Actelion:
-- Reimbursement status achieved in Australia
-- Labeling questions received from Japanese regulator
-- Limited...
Actelion and Merck Form Renin Inhibitor Alliance
December 04, 2003 01:19 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland and WHITEHOUSE STATION, N.J., Dec. 04, 2003 (PRIMEZONE) -- Actelion:
-- Actelion to advance its break-through discoveries of new classes
of renin inhibitors...
Actelion presents its Research and Development efforts
October 29, 2003 01:14 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, Oct. 29, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today provided a comprehensive overview of its preclinical and clinical pipeline at its R&D Day in London (UK)....
Actelion announces 9-month results for 2003
October 28, 2003 01:33 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, Oct. 28, 2003 (PRIMEZONE) -- Actelion (SWX:ATLN) (Other OTC:ALIOF)
-- Strong Tracleer(R) sales in Pulmonary Arterial Hypertension
result in an operating profit...
Actelion Ltd. Invitation to webcast and conference call
October 23, 2003 10:54 ET
|
Actelion Ltd.
ALLSCHWIL, Switzerland, Oct. 23, 2003 (PRIMEZONE) -- Actelion announces the 9 months 2003 results on 28th October 2003.
Actelion Research and Development Day 2003 on 29th October 2003
Dear Friend...
Actelion acquires privately held Axovan AG: Integration will strengthen both late-stage development pipeline and early drug discovery efforts
September 30, 2003 01:27 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, Sept. 30, 2003 (PRIMEZONE) --
- Actelion to further develop intravenous endothelin receptor
antagonist optimized for cerebral indications currently in
Phase...
HIV Patients with Pulmonary Arterial Hypertension (PAH): Results of Treatment with Oral Tracleer (bosentan)
September 02, 2003 01:57 ET
|
Actelion Ltd.
ALLSSHWIL, Switzerland, Sept. 02, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA)...
US Food and Drug Administration approves Zavesca
August 01, 2003 02:35 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, July 31, 2003 (PRIMEZONE) -- Actelion Ltd (SWX: ATLN) today announced that the US Food and Drug Administration (FDA) has approved Zavesca(r) (miglustat) capsules the first oral...
Actelion Ltd. and Axovan AG Enter Research Collaboration
June 17, 2003 01:47 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland, June 17, 2003 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) and privately held Axovan AG announced today that they have entered into a research collaboration. The two...
Actelion to further strengthen its research efforts
June 02, 2003 17:11 ET
|
Actelion Ltd.
ALLSCHWIL/BASEL, Switzerland/SAN DIEGO, , June 02, 2003 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) and Discovery Partners International, Inc. (Nasdaq:DPII) today announced that the two companies have...